Travere Therapeutics (TVTX) Assets Average (2011 - 2026)

Travere Therapeutics' Assets Average history runs 16 years deep, the most recent figure standing at $580.2 million for Q1 2026.

• Quarterly Assets Average rose 1.53% year-over-year to $580.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $580.2 million (up 1.53% YoY) and the FY2025 annual result came in at $599.7 million, down 13.28% from the prior year.
• Assets Average was $580.2 million for Q1 2026 at Travere Therapeutics, up from $571.9 million in the prior quarter.
• Across five years, Assets Average topped out at $810.9 million in Q4 2023 and bottomed at $527.8 million in Q3 2024.
• A 5-year average of $670.6 million and a median of $699.4 million in 2022 frame the typical range for Assets Average.
• Annual changes were most pronounced in 2022 — Assets Average advanced 17.03% — and 2024, when it slumped 32.74%.
• Travere Therapeutics' Assets Average stood at $699.4 million in 2022, then climbed by 15.94% to $810.9 million in 2023, then slumped by 32.26% to $549.3 million in 2024, then grew by 4.12% to $571.9 million in 2025, then increased by 1.45% to $580.2 million in 2026.
• Business Quant data shows TVTX's Assets Average at $580.2 million in Q1 2026, $571.9 million in Q4 2025, and $546.9 million in Q3 2025.